The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers
Table 5
Analyses of tumour-infiltrating CD1a+ dendritic cells and CD66b+ neutrophils in the breast tumours in women with LLABCs and subsequent PCR following NAC.
Cell subsets
Groups
Pre-NAC intratumoural median (range)(3)
value(3) (GPR versus PRR, PCR versus non-PCR)
Pre-NAC peritumoural median (range)(3)
value(4) (GPR versus PRR, PCR versus non-PCR)
CD1a+ ()
Good pathological response (GPR, )
3 (1–104)
0.837
1 (1–16)
0.837
Poor pathological response (PPR, )
11 (0–63)
2 (0–11)
Pathological complete response (PCR, )
3 (1–104)
0.713
1.5 (1–16)
0.492
Nonpathological complete response (non-PCR, )
4 (0–63)
1.5 (0–11)
CD66b+ ()
Good pathological response (GPR, )
2 (0–53)
0.174
2 (0–71)
0.408
Poor pathological response (PPR, )
1 (0–3)
1 (0–2)
Pathological complete response (PCR, )
3 (0–53)
0.181
5 (0–71)
0.118
Nonpathological complete response (non-PCR, )
1 (0–3)
1 (0–2)
LLABCs: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; (3)total cell count per 5 high-power fields (core biopsies of breast cancers); (4)Mann–Whitney U test.
